journal
https://read.qxmd.com/read/38834850/proteomic-analysis-of-cardiorespiratory-fitness-for-prediction-of-mortality-and-multisystem-disease-risks
#41
JOURNAL ARTICLE
Andrew S Perry, Eric Farber-Eger, Tomas Gonzales, Toshiko Tanaka, Jeremy M Robbins, Venkatesh L Murthy, Lindsey K Stolze, Shilin Zhao, Shi Huang, Laura A Colangelo, Shuliang Deng, Lifang Hou, Donald M Lloyd-Jones, Keenan A Walker, Luigi Ferrucci, Eleanor L Watts, Jacob L Barber, Prashant Rao, Michael Y Mi, Kelley Pettee Gabriel, Bjoern Hornikel, Stephen Sidney, Nicholas Houstis, Gregory D Lewis, Gabrielle Y Liu, Bharat Thyagarajan, Sadiya S Khan, Bina Choi, George Washko, Ravi Kalhan, Nick Wareham, Claude Bouchard, Mark A Sarzynski, Robert E Gerszten, Soren Brage, Quinn S Wells, Matthew Nayor, Ravi V Shah
Despite the wide effects of cardiorespiratory fitness (CRF) on metabolic, cardiovascular, pulmonary and neurological health, challenges in the feasibility and reproducibility of CRF measurements have impeded its use for clinical decision-making. Here we link proteomic profiles to CRF in 14,145 individuals across four international cohorts with diverse CRF ascertainment methods to establish, validate and characterize a proteomic CRF score. In a cohort of around 22,000 individuals in the UK Biobank, a proteomic CRF score was associated with a reduced risk of all-cause mortality (unadjusted hazard ratio 0...
June 4, 2024: Nature Medicine
https://read.qxmd.com/read/38834849/heritable-and-spatial-immunogenic-traits-co-predict-the-efficacy-of-immunotherapy-in-kidney-cancer
#42
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
June 4, 2024: Nature Medicine
https://read.qxmd.com/read/38834848/cervical-cancer-screening-using-dna-methylation-triage-in-a-real-world-population
#43
JOURNAL ARTICLE
Lena Schreiberhuber, James E Barrett, Jiangrong Wang, Elisa Redl, Chiara Herzog, Charlotte D Vavourakis, Karin Sundström, Joakim Dillner, Martin Widschwendter
Cervical cancer (CC) screening in women comprises human papillomavirus (HPV) testing followed by cytology triage of positive cases. Drawbacks, including cytology's low reproducibility and requirement for short screening intervals, raise the need for alternative triage methods. Here we used an innovative triage technique, the WID-qCIN test, to assess the DNA methylation of human genes DPP6, RALYL and GSX1 in a real-life cohort of 28,017 women aged ≥30 years who attended CC screening in Stockholm between January and March 2017...
June 4, 2024: Nature Medicine
https://read.qxmd.com/read/38834847/non-literacy-biased-culturally-fair-cognitive-detection-tool-in-primary-care-patients-with-cognitive-concerns-a-randomized-controlled-trial
#44
JOURNAL ARTICLE
Joe Verghese, Rachel Chalmer, Marnina Stimmel, Erica Weiss, Jessica Zwerling, Rubina Malik, David Rasekh, Asif Ansari, Roderick A Corriveau, Amy R Ehrlich, Cuiling Wang, Emmeline Ayers
Dementia is often undiagnosed in primary care, and even when diagnosed, untreated. The 5-Cog paradigm, a brief, culturally adept, cognitive detection tool paired with a clinical decision support may reduce barriers to improving dementia diagnosis and care. We performed a randomized controlled trial in primary care patients experiencing health disparities (racial/ethnic minorities and socioeconomically disadvantaged). Older adults with cognitive concerns were assigned in a 1:1 ratio to the 5-Cog paradigm or control...
June 4, 2024: Nature Medicine
https://read.qxmd.com/read/38831115/reducing-the-risk-of-highly-pathogenic-avian-influenza-a-virus-h5n1-transmission-during-the-hajj
#45
Shahul H Ebrahim, Alimuddin Zumla, Justin Wong, Mujeeb Ur Rahman, Seif S Al-Abri, Abdullah A Al Rabeeah, Ziad A Memish
No abstract text is available yet for this article.
June 3, 2024: Nature Medicine
https://read.qxmd.com/read/38830994/isatuximab-lenalidomide-dexamethasone-and-bortezomib-in-transplant-ineligible-multiple-myeloma-the-randomized-phase-3-benefit-trial
#46
JOURNAL ARTICLE
Xavier Leleu, Cyrille Hulin, Jerome Lambert, Arthur Bobin, Aurore Perrot, Lionel Karlin, Murielle Roussel, Lydia Montes, Brieuc Cherel, Thomas Chalopin, Borhane Slama, Marie-Lorraine Chretien, Kamel Laribi, Claire Dingremont, Christophe Roul, Clara Mariette, Sophie Rigaudeau, Claire Calmettes, Mamoun Dib, Mourad Tiab, Laure Vincent, Jacques Delaunay, Alberto Santagostino, Margaret Macro, Emmanuelle Bourgeois, Frederique Orsini-Piocelle, Julie Gay, Benoit Bareau, Noemie Bigot, François Vergez, Pierre Lebreton, Reza Tabrizi, Agathe Waultier-Rascalou, Laurent Frenzel, Ronan Le Calloch, Emilie Chalayer, Thorsten Braun, Florence Lachenal, Selim Corm, Celine Kennel, Rakiba Belkhir, Jean-Sebastien Bladé, Bertrand Joly, Valentine Richez-Olivier, Helene Gardeney, Helene Demarquette, Daniela Robu-Cretu, Laurent Garderet, Muriel Newinger-Porte, Amine Kasmi, Bruno Royer, Olivier Decaux, Bertrand Arnulf, Karim Belhadj, Cyrille Touzeau, Mohamad Mohty, Salomon Manier, Philippe Moreau, Hervé Avet-Loiseau, Jill Corre, Thierry Facon
CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) and is considered the best standard of care (SOC). To improve current SOC, we evaluated the added value of weekly bortezomib (V) to isatuximab plus lenalidomide and dexamethasone (IsaRd versus Isa-VRd). This Intergroupe Francophone of Myeloma phase 3 study randomized 270 patients with NDMM that were TI, aged 65-79 years, to IsaRd versus Isa-VRd arms...
June 3, 2024: Nature Medicine
https://read.qxmd.com/read/38830993/geographic-sources-of-ozone-air-pollution-and-mortality-burden-in-europe
#47
JOURNAL ARTICLE
Hicham Achebak, Roger Garatachea, María Teresa Pay, Oriol Jorba, Marc Guevara, Carlos Pérez García-Pando, Joan Ballester
Ground-level ozone (O3 ) is a harmful air pollutant formed in the atmosphere by the interaction between sunlight and precursor gases. Exposure to current O3 levels in Europe is a major source of premature mortality from air pollution. However, mitigation actions have been mainly designed and implemented at the national and regional scales, lacking a comprehensive assessment of the geographic sources of O3 pollution and its associated health impacts. Here we quantify both national and imported contributions to O3 and their related mortality burden across 813 contiguous regions in 35 European countries, representing about 530 million people...
June 3, 2024: Nature Medicine
https://read.qxmd.com/read/38830992/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results
#48
JOURNAL ARTICLE
Changsong Qi, Chang Liu, Jifang Gong, Dan Liu, Xicheng Wang, Panpan Zhang, Yanru Qin, Sai Ge, Miao Zhang, Zhi Peng, Jun Zhou, Zhihao Lu, Ming Lu, Yanshuo Cao, Jiajia Yuan, Yakun Wang, Zhenghang Wang, Ran Xue, Xiaohui Peng, Yumeng Wang, Daijing Yuan, Jian Li, Xiaotian Zhang, Lin Shen
Claudin18.2 (CLDN18.2) is highly expressed with the development of various malignant tumors, especially gastrointestinal cancers, and is emerging as a new target for cancer treatment. Satricabtagene autoleucel (satri-cel)/CT041 is an autologous chimeric antigen receptor (CAR) T cell targeting CLDN18.2, and the interim results of the CT041-CG4006 trial were reported in June 2022. Here we present the final results of this single-arm, open-label, phase 1 trial, which evaluated the safety and efficacy of satri-cel in patients with CLDN18...
June 3, 2024: Nature Medicine
https://read.qxmd.com/read/38830991/lisocabtagene-maraleucel-in-follicular-lymphoma-the-phase-2-transcend-fl-study
#49
JOURNAL ARTICLE
Franck Morschhauser, Saurabh Dahiya, M Lia Palomba, Alejandro Martin Garcia-Sancho, Juan Luis Reguera Ortega, John Kuruvilla, Ulrich Jäger, Guillaume Cartron, Koji Izutsu, Martin Dreyling, Brad Kahl, Hervé Ghesquieres, Kirit Ardeshna, Hideki Goto, Anna Maria Barbui, Jeremy S Abramson, Peter Borchmann, Isabelle Fleury, Stephan Mielke, Alan Skarbnik, Sven de Vos, Manali Kamdar, Reem Karmali, Andreas Viardot, Thalia Farazi, Omotayo Fasan, James Lymp, Min Vedal, Rina Nishii, Ariel Avilion, Jessica Papuga, Jinender Kumar, Loretta J Nastoupil
An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of disease within 24 months (POD24) from first-line immunochemotherapy or disease refractory to both CD20-targeting agent and alkylator (double refractory), due to no established standard of care and poor outcomes. Chimeric antigen receptor (CAR) T cell therapy is an option in R/R FL after two or more lines of prior systemic therapy, but there is no consensus on its optimal timing in the disease course of FL, and there are no data in second-line (2L) treatment of patients with high-risk features...
June 3, 2024: Nature Medicine
https://read.qxmd.com/read/38825627/trastuzumab-deruxtecan-versus-trastuzumab-emtansine-in-her2-positive-metastatic-breast-cancer-long-term-survival-analysis-of-the-destiny-breast03-trial
#50
JOURNAL ARTICLE
Javier Cortés, Sara A Hurvitz, Seock-Ah Im, Hiroji Iwata, Giuseppe Curigliano, Sung-Bae Kim, Joanne W Y Chiu, Jose L Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Hamilton
Trastuzumab deruxtecan (T-DXd) demonstrated significantly improved efficacy over trastuzumab emtansine (T-DM1) in DESTINY-Breast03 (median follow-up, 28 months). We report updated efficacy and safety analyses, including secondary and exploratory efficacy endpoints (median follow-up, 41 months) of DESTINY-Breast03. Patients with advanced HER2-positive metastatic breast cancer previously treated with taxane and trastuzumab were randomized to T-DXd (5.4 mg per kg (261 patients)) or T-DM1 (3.6 mg per kg (263 patients))...
June 2, 2024: Nature Medicine
https://read.qxmd.com/read/38824959/cell-free-dna-for-the-detection-of-kidney-allograft-rejection
#51
JOURNAL ARTICLE
Olivier Aubert, Cindy Ursule-Dufait, Romain Brousse, Juliette Gueguen, Maud Racapé, Marc Raynaud, Elisabet Van Loon, Angelica Pagliazzi, Edmund Huang, Stanley C Jordan, Kenneth D Chavin, Gaurav Gupta, Dhiren Kumar, Tarek Alhamad, Sanjiv Anand, Jorge Sanchez-Garcia, Basmah A Abdalla, Julien Hogan, Rouba Garro, Darshana M Dadhania, Pranjal Jain, Didier A Mandelbrot, Maarten Naesens, Raja Dandamudi, Vikas R Dharnidharka, Dany Anglicheau, Carmen Lefaucheur, Alexandre Loupy
Donor-derived cell-free DNA (dd-cfDNA) is an emerging non-invasive biomarker that has the potential to detect allograft injury. The capacity of donor-derived cell-free DNA to detect kidney allograft rejection and its added clinical value beyond standard of care patient monitoring is unclear. We enrolled 2,882 kidney allograft recipients from 14 transplantation centers in Europe and the US in an observational population-based study. The primary analysis included 1,134 patients. Donor-derived cell-free DNA levels strongly correlated with allograft rejection including antibody-mediated rejection (p < 0...
June 2, 2024: Nature Medicine
https://read.qxmd.com/read/38824244/inhibition-of-lysine-acetyltransferase-kat6-in-er-her2-metastatic-breast-cancer-a-phase-1-trial
#52
JOURNAL ARTICLE
Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon Liyanage, Michelle Saul, Christophe Le Corre, Athanasia Skoura, Li Liu, Meng Li, Patricia M LoRusso
Inhibition of histone lysine acetyltransferases (KATs) KAT6A and KAT6B has shown antitumor activity in estrogen receptor-positive (ER+ ) breast cancer preclinical models. PF-07248144 is a selective catalytic inhibitor of KAT6A and KAT6B. In the present study, we report the safety, pharmacokinetics (PK), pharmacodynamics, efficacy and biomarker results from the first-in-human, phase 1 dose escalation and dose expansion study (n = 107) of PF-07248144 monotherapy and fulvestrant combination in heavily pretreated ER+ human epidermal growth factor receptor-negative (HER2- ) metastatic breast cancer (mBC)...
June 1, 2024: Nature Medicine
https://read.qxmd.com/read/38824243/surgery-versus-no-surgery-in-platinum-sensitive-relapsed-ovarian-cancer-final-overall-survival-analysis-of-the-soc-1-randomized-phase-3-trial
#53
JOURNAL ARTICLE
Rong Jiang, Yanling Feng, Yulian Chen, Xi Cheng, Tingyan Shi, Wen Gao, Huixun Jia, Shiyang Jiang, Yi Guo, Xiao Huang, Dongsheng Tu, Yuqin Zhang, Huijuan Yang, Ping Zhang, Jihong Liu, Jianqing Zhu, Rongyu Zang
Surgery for platinum-sensitive, relapsed ovarian cancer (PSROC) is widely practiced but had contradictory survival outcomes in previous studies. In this multicenter, open-label, phase 3 trial, women with PSROC, and having had one previous therapy and no platinum-based chemotherapy (platinum-free interval) of 6 months or more, were randomly assigned to either the surgery group (182 patients) or the no-surgery group (control) (175 patients). Patients with resectable diseases were eligible according to the international model (iMODEL), combined with a positron emission tomography-computed tomography imaging...
June 1, 2024: Nature Medicine
https://read.qxmd.com/read/38824242/fruquintinib-plus-paclitaxel-versus-placebo-plus-paclitaxel-for-gastric-or-gastroesophageal-junction-adenocarcinoma-the-randomized-phase-3-frutiga-trial
#54
JOURNAL ARTICLE
Feng Wang, Lin Shen, Weijian Guo, Tianshu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yueyin Pan, Yongqian Shu, Fuyou Zhao, Ying Cheng, Feng Ye, Kangsheng Gu, Tao Zhang, Hongming Pan, Haijun Zhong, Fuxiang Zhou, Yanru Qin, Lei Yang, Weidong Mao, Qiu Li, Wenxiang Dai, Wei Li, Shubin Wang, Yong Tang, Dong Ma, Xianli Yin, Yanhong Deng, Ying Yuan, Man Li, Wenwei Hu, Donghui Chen, Guoxin Li, Qiqi Liu, Panfeng Tan, Songhua Fan, Michael Shi, Weiguo Su, Rui-Hua Xu
The vascular endothelial growth factor pathway plays a key role in the pathogenesis of gastric cancer. In the multicenter, double-blind phase 3 FRUTIGA trial, 703 patients with advanced gastric or gastroesophageal junction adenocarcinoma who progressed on fluorouracil- and platinum-containing chemotherapy were randomized (1:1) to receive fruquintinib (an inhibitor of vascular endothelial growth factor receptor-1/2/3; 4 mg orally, once daily) or placebo for 3 weeks, followed by 1 week off, plus paclitaxel (80 mg/m2 intravenously on days 1/8/15 per cycle)...
June 1, 2024: Nature Medicine
https://read.qxmd.com/read/38823511/pembrolizumab-for-advanced-urothelial-carcinoma-exploratory-ctdna-biomarker-analyses-of-the-keynote-361-phase-3-trial
#55
JOURNAL ARTICLE
Thomas Powles, Yen-Hwa Chang, Yoshiaki Yamamoto, Jose Munoz, Felipe Reyes-Cosmelli, Avivit Peer, Graham Cohen, Evan Y Yu, Anja Lorch, Abhishek Bavle, Blanca Homet Moreno, Julia Markensohn, Mackenzie Edmondson, Cai Chen, Razvan Cristescu, Carol Pena, Jared Lunceford, Seyda Gunduz
Circulating tumor DNA (ctDNA) is emerging as a potential biomarker in early-stage urothelial cancer but its utility in metastatic disease remains unknown. In the phase 3 KEYNOTE-361 study, pembrolizumab with and without chemotherapy was compared with chemotherapy alone in patients with metastatic urothelial cancer. The study did not meet prespecified efficacy thresholds for statistical significance. To identify potential biomarkers of response, we retrospectively evaluated association of pre- and post-treatment ctDNA with clinical outcomes in a subset of patients who received pembrolizumab (n = 130) or chemotherapy (n = 130) in KEYNOTE-361...
June 1, 2024: Nature Medicine
https://read.qxmd.com/read/38822130/building-trust-and-transparency-in-biomedical-sciences-through-data-walks
#56
LETTER
Layla Fattah, Jay Johnson, Uraina Clark, Leona Hess, Ann-Gel Palermo, Dania M Figueroa Acosta, Talia H Swartz
No abstract text is available yet for this article.
May 31, 2024: Nature Medicine
https://read.qxmd.com/read/38821540/mutations-in-the-u4-snrna-gene-rnu4-2-cause-one-of-the-most-prevalent-monogenic-neurodevelopmental-disorders
#57
JOURNAL ARTICLE
Daniel Greene, Chantal Thys, Ian R Berry, Joanna Jarvis, Els Ortibus, Andrew D Mumford, Kathleen Freson, Ernest Turro
Most people with intellectual disability (ID) do not receive a molecular diagnosis following genetic testing. To identify new etiologies of ID, we performed a genetic association analysis comparing the burden of rare variants in 41,132 non-coding genes between 5,529 unrelated cases and 46,401 unrelated controls. RNU4-2, which encodes U4 snRNA, a critical component of the spliceosome, was the most strongly associated gene. We implicated de novo variants among 47 cases in two regions of RNU4-2 in the etiology of a syndrome characterized by ID, microcephaly, short stature, hypotonia, seizures and motor delay...
May 31, 2024: Nature Medicine
https://read.qxmd.com/read/38816621/tumor-infiltrating-lymphocyte-approval-heralds-new-era-for-precision-cancer-immunotherapy
#58
Natalie Healey
No abstract text is available yet for this article.
May 30, 2024: Nature Medicine
https://read.qxmd.com/read/38816611/author-correction-combined-inhibition-of-bet-family-proteins-and-histone-deacetylases-as-a-potential-epigenetics-based-therapy-for-pancreatic-ductal-adenocarcinoma
#59
Pawel K Mazur, Alexander Herner, Stephano S Mello, Matthias Wirth, Simone Hausmann, Francisco J Sánchez-Rivera, Shane M Lofgren, Timo Kuschma, Stephan A Hahn, Deepak Vangala, Marija Trajkovic-Arsic, Aayush Gupta, Irina Heid, Peter B Noël, Rickmer Braren, Mert Erkan, Jörg Kleeff, Bence Sipos, Leanne C Sayles, Mathias Heikenwalder, Elisabeth Heßmann, Volker Ellenrieder, Irene Esposito, Tyler Jacks, James E Bradner, Purvesh Khatri, E Alejandro Sweet-Cordero, Laura D Attardi, Roland M Schmid, Guenter Schneider, Julien Sage, Jens T Siveke
No abstract text is available yet for this article.
May 30, 2024: Nature Medicine
https://read.qxmd.com/read/38816610/point-of-care-testing-for-sepsis-in-remote-australia-and-for-first-nations-peoples
#60
LETTER
Brooke Spaeth, Sean Taylor, Mark Shephard, Richard L Reed, Rodney Omond, Jonathan Karnon, Billie Bonevski, Chris Rissel, Shahid Ullah, Tina Noutsos, Jacqueline H Stephens, James A Smith, Annabelle Wilson, Brett Abbenbroek, Emma de Courcy-Ireland, Simon Finfer
No abstract text is available yet for this article.
May 30, 2024: Nature Medicine
journal
journal
32162
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.